Skip to main content

Table 3 Univariate and multivariate analyses in the primary cohort

From: Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature

Variables Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.002 (0.986–1.018) 0.853   
T stage
 T1 Referent    
 T2 1.631 (0.980–2.714) 0.060   
 T3 2.027 (1.060–3.876) 0.033   
 T4 5.748 (2.394–13.805)  < 0.001   
N stage
 N0 Referent    
 N1 1.611 (1.004–2.585) 0.048   
 N2 2.282 (1.219–4.269) 0.010   
 N3 4.651 (2.425–8.921)  < 0.001   
 Nx 15.987 (6.600–38.722)  < 0.001   
TNM stage
 I Referent   Referent  
 II 1.641 (0.850–3.167) 0.140 1.589 (0.820–3.077 0.170
 III 3.589 (1.824–7.061) < 0.001 4.015 (2.010–8.020) < 0.001
 Unknown 13.559 (5.415–33.951) < 0.001 12.054 (4.623–31.430) < 0.001
ER status
 Negative Referent    
 Positive 0.562 (0.369–0.855) 0.007   
 Unknown 1.097 (0.426–2.825) 0.848   
PR status
 Negative Referent    
 Positive 0.550 (0.369–0.821) 0.003   
 Unknown 1.120 (0.442–2.838) 0.811   
Tumor subtype
 HR+/HER2− Referent   Referent  
 HR+/HER2+ 0.756 (0.339–1.687) 0.495 0.792 (0.354–1.774) 0.571
 HR−/HER2+ 1.744 (0.624–4.872) 0.289 0.924 (0.320–2.672) 0.884
 TNBC 2.038 (1.204–3.450) 0.008 2.318 (1.359–3.955) 0.002
 Unknown 2.591 (1.572–4.269)  < 0.001 1.922 (1.153–3.204) 0.012
 Risk score 2.718(1.903–3.884)  < 0.001 2.975 (2.028–4.364)  < 0.001
  1. CI confidence interval, HR hazard ratios, ER estrogen receptor, PR progesterone receptor, HER2, human epithelial growth factor receptor 2
  2. Italic values indicate statistical significance (P < 0.05)